Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.74 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.74 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.74 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.74 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.74 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.74 |
| ▸ | TAS2R14 | Q9NYV8 | 16/20 | 0.71 |
| ▸ | PTGES | O14684 | 1/20 | 0.65 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.65 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.65 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.59 |
| ▸ | BMP1 | P13497 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287409 | 0.89 | BMP1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287463 | 0.86 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287441 | 0.85 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1279804 | 0.83 | TAS2R14 (1.00) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL1279372 | 0.82 | TAS2R14 (1.00) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL1278960 | 0.82 | TAS2R14 (1.00) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL1278905 | 0.82 | TAS2R14 (0.80) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL1279288 | 0.81 | TAS2R14 (1.00) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL1279042 | 0.80 | TAS2R14 (1.00) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL1169926 | 0.79 | TAS2R14 (1.00) | TAS2R14PTGESTAS2R8CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | BACE1, BACE2, GSAP | PSEN1 4/4885PSEN2 5/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.